Comparative Pharmacology
Head-to-head clinical analysis: PIMOZIDE versus THIOTHIXENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMOZIDE versus THIOTHIXENE.
PIMOZIDE vs THIOTHIXENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks dopamine D2, D3, and D4 receptors; also 5-HT2A, α1-adrenergic, and H1 receptors.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the brain. It also has alpha-adrenergic and histamine H1 blocking activity, with minimal anticholinergic effects.
1-10 mg orally once daily; maximum 10 mg/day.
Initial: 2 mg orally three times daily; maintenance: 5-30 mg/day orally in divided doses; maximum: 60 mg/day. IM: 4 mg 2-4 times daily; maximum 30 mg/day.
MODERATE Risk
MODERATE Risk
Terminal elimination half-life is approximately 50-60 hours in adults; may be prolonged in elderly or hepatic impairment.
Clinical Note
moderatePimozide + Levofloxacin
"Pimozide may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderatePimozide + Norfloxacin
"Pimozide may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePimozide + Gemifloxacin
"Pimozide may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateThiothixene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Thiothixene."
Terminal half-life: 10-20 hours (mean ~14 h). Clinical context: Steady-state achieved in ~2-3 days; allows once-daily dosing for maintenance.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 70-90% of eliminated drug; fecal excretion ~10-30%.
Primarily renal: 65-70% as metabolites, <1% unchanged. Fecal: 15-20% via biliary elimination.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic